Background: Identifying the prescribing physician may be essential in studies that use health care claims databases but often there is no single consistent physician identifier (ID) available that spans an entire database and no standard methods have emerged to address this issue.
Methods: Unique Drug Enforcement Administration (DEA) numbers (N=36,721) were identified from the pharmacy claims of a cohort of postmenopausal (55+) initiators of osteoporosis medications (2008-2011) in the United Healthcare database. The proportion of times a Provider ID appeared at least once on the outpatient medical service claims (OMSCs) in the 14 days before a new prescription (Rx) out of the total number of new Rxs for each DEA was calculated and the Provider ID with the highest proportion was considered the most likely match to the DEA. We used regression models to evaluate how characteristics of OMSCs (N=36,721) related to the probability that the provider would be the prescribing physician on a proximal pharmacy claim for each patient (N=20,058).
Results: A total of 37,448,056 new Rxs and 132,135,673 OMSCs were associated with the DEAs. Family and general practitioner, hospitalist, and osteoporosis diagnoses were strong predictors of a match. Our models had sensitivities ranging from 81.9% to 82.8% and specificities ranging from 52.4% to 53.5%.
Conclusions: Our algorithms were good at identifying matches for the prescribing physician according to our reference standard but may have included some false positives. Predicted probabilities from our models could be used in other databases where physician IDs are unavailable to help identify the prescriber.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MLR.0000000000001334 | DOI Listing |
BMJ Open
December 2024
Centre for Health Services and Policy Research, The University of British Columbia, Vancouver, British Columbia, Canada.
Objectives: To describe the population that meets the criteria for major depressive disorder (MDD) in British Columbia (BC), compare patterns of healthcare utilisation between those with MDD who are and are not prescribed pharmacotherapy, and assess these relationships in models that control for potential confounding variables.
Design: We used a population cross-sectional study design among a cohort of individuals living with MDD and examined the relationship between pharmacotherapy and healthcare utilisation between 2019 and 2020 using linked billing and administrative data.
Setting: This study identified individuals with MDD using a validated case definition of International Classification of Diseases (ICD) codes in BC, Canada.
BMJ Open
December 2024
Department of Microbiology and Mycology, National Institute of Preventive and Social Medicine, Dhaka, Bangladesh.
Background: Antimicrobial resistance (AMR) is a global health and development concern. Antimicrobial misuse and overuse are key contributors to the emergence of drug-resistant infections.
Objective: The current study aimed to determine the level of perception and practices of physicians regarding AMR in a tertiary-level hospital.
Int Clin Psychopharmacol
January 2025
Department of Affective Disorders, Jagiellonian University Medical College; Kopernika 21a, 31-501 Kraków, Poland.
This study aims to elucidate current trends in clinical practice for managing depression in elderly patients, focusing on the utilization of pharmacotherapeutics and integrated care models to improve patient outcomes. A comprehensive survey was conducted among physicians from various European countries to gather insights into prescribing habits, treatment patterns, and the impact of comorbidities on therapeutic choices, with a focus on trazodone. The participants included psychiatrists, general practitioners, and neurologists actively involved in elderly depression care.
View Article and Find Full Text PDFCureus
December 2024
Medical Oncology, Healthcare Global Enterprises (HCG) Cancer Center, Bangalore, IND.
Background Clinicians use prognostic biomarker/multi-gene-based tests for predicting recurrence in hormone receptor-positive/HER2-negative (HR+/HER2-) early-stage breast cancer (EBC). CanAssist Beast (CAB) uses the expression of five protein biomarkers in combination with tumor-specific parameters such as tumor size, histopathological grade, and lymph node status to predict the risk of distant recurrence within five years of diagnosis for patients with HR+/HER2-, EBC. The current study aimed to evaluate the impact of prognostic tests on adjuvant chemotherapy decisions by assessing the agreement between clinical and CAB risk stratification as low-risk (LR) or high-risk (HR) for distant recurrence.
View Article and Find Full Text PDFEuroasian J Hepatogastroenterol
December 2024
Department of Hepatology, Sheikh Hasina Medical College Hospital, Tangail, Bangladesh.
Background: The strong association between type 2 diabetes mellitus (T2DM) and fatty liver is well known, and its nomenclature has even recently changed to metabolic dysfunction-associated steatotic liver disease (MASLD). Healthy MASLD patients are frequently overlooked and maltreated, especially in Bangladesh. In this present study, we tried to correlate T2DM burden in apparently healthy, incidentally diagnosed fatty liver patients on ultrasound.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!